Kyverna Therapeutics News

UBS Initiates Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $13

Moomoo NewsOct 11 09:33 ET

Kyverna Therapeutics Initiated With a Buy at UBS

TipRanksOct 10 05:45 ET

Rodman & Renshaw Initiates Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $16

Moomoo NewsOct 10 04:34 ET

Kyverna Therapeutics Initiated With a Buy at Rodman & Renshaw

TipRanksOct 9 06:47 ET

Kyverna Therapeutics Analyst Ratings

BenzingaSep 19 06:55 ET

Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsSep 19 06:31 ET

H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Hold Rating, Maintains Target Price $7

Moomoo NewsSep 19 06:31 ET

Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsSep 17 07:31 ET

J.P. Morgan Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $33

Moomoo NewsSep 13 06:31 ET

Kyverna Therapeutics Analyst Ratings

BenzingaAug 15 07:28 ET

Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Smith Douglas Homes Corp. Class A (SDHC) and Kayne Anderson BDC, Inc. (KBDC)

TipRanksAug 15 06:34 ET

H.C. Wainwright Initiates Kyverna Therapeutics(KYTX.US) With Hold Rating, Announces Target Price $7

Moomoo NewsAug 15 06:31 ET

Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsAug 14 09:33 ET

Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsAug 14 07:35 ET

Kyverna Therapeutics Analyst Ratings

BenzingaJul 31 14:38 ET

Kyverna Therapeutics Analyst Ratings

BenzingaJul 16 07:58 ET

Kyverna Therapeutics Analyst Ratings

BenzingaJul 3 06:21 ET

Kyverna Therapeutics Analyst Ratings

BenzingaMar 4 06:10 ET